Abstract
Objective
Lutetium-177 (Lu177) prostate-specific membrane antigen (Lu177 PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (CRPC). The purpose of the study was to determine the molecular volumetric Gallium-68 (Ga68) PSMA PET/CT parameters that can predict patients who will respond to treatment.
Methods
These single-center retrospective data were obtained from metastatic CRPC patients receiving intravenous 6.0–8.5 GBq Lu177 PSMA treatment every 6–8 weeks for a maximum of 3–8 cycles, with baseline Ga68 PSMA PET/CT scan, clinical data, and information on treatment responses. All lesions were divided into two groups according to the increase and decrease in PSMA expression levels of 600 bone lesions and 85 lymph nodes that were compatible with metastasis of 23 patients after the treatment. The primary endpoint of our study was the evaluation of the relation between the baseline SUVmax, PSMA TV, TL PSMA values, and the treatment response of the two groups. The threshold values were determined for the parameters that had significant relations. In the present study, the prostate-specific antigen (PSA) response and treatment-induced toxicities were also evaluated as the secondary endpoint.
Results
It was found that SUVmax, PSMA TV, and TL PSMA values in bone metastases showed significant differences between the groups with decreased and increased PSMA expression levels after the treatment. The AUC value for SUVmax was significant (AUC = 0.677; p < 0.001). The cutoff value was > 10.50 (sensitivity = 91.8%, Specificity = 41.5%) for SUVmax, > 1.50 cm3 (sensitivity = 49.1%, specificity = 70%) for PSMA TV and > 8.50 g (sensitivity = %60.9, specificity = %72.2) for TL PSMA. The median SUVmax value before the treatment in all metastatic lymph nodes was found to be 7.1 (5.4–12.4), and the median SUVmax after the treatment was 2.5 (1.6–12.1) (p < 0.001).
Conclusion
It was shown in the present study that Lu177 PSMA treatment response may be higher in CRPC patients with metastatic bone lesion with high baseline PSMA expression level, and better treatment response may be achieved in patients with lymph node metastases than in bone metastases.
Similar content being viewed by others
References
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practi- cal aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60.
Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [Lu177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.
Heck MM, Tauber R, Schwaiger S, Retz M, Alessadria CD, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with Lu177-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920–6.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [Lu177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322.
Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, et al. Ga68-PSMA I&T PET/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):168–77.
Okudan B, Coşkun N, Seven B, Atalay MA, Yıldırım A, Görtan FA. Assessment of volumetric parameters derived from Ga68-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience. Nucl Med Commun. 2021;42(11):1254–60.
Grubmüller B, Senn D, Kramer G, Baltzer P, Andreal DD, Grubmüller KH, et al. Response assessment using Ga68-PSMA ligand PET in patients undergoing Lu177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1063–72.
Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, Mallek D, et al. Ga68-PSMA PET/CT for monitoring response to Lu177-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1054–62.
Acar E, Özdoğan Ö, Aksu A, Derebek E, Bekiş R, Kaya GÇ. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Ann Nucl Med. 2019;33(9):681–8.
Kim JH. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review. Oncotarget. 2016;7(36):58105–10.
Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC crite- ria and clues to future developments. Eur J Nucl Med Mol Imag- ing. 2017;44(Suppl 1):55–66.
Seifert R, Seitzer K, Herrmann K, Kessel K, Schäfers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving Lu177-PSMA-617 Radioligand Therapy. Theranostics. 2020;10(17):7812–20.
Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786–9.
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christian-sen H, Wester HJ, et al. Initial experience with volumetric (68) Ga-PSMA I&T PET/CT for assessment of whole-body tumor bur- den as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962–8.
Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [Ga68]Ga-PSMA-11 PET/CT independently predicts overall survival in [Lu177]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05594-8.
Khurshid Z, Ahmadzadehfar H, Gaertner FC, Papp L, Zsoter N, Essler M, et al. Bundschuh Role of textural heterogeneity parameters in patient selection for Lu177-PSMA therapy via response prediction. Oncotarget. 2018;9(70):33312–21.
Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of 177 Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17(1):15–22.
Schmidkonz C, Cordes M, Schmidt D, Bäuerle T, Goetz TI, Beck M, et al. Ga68-PSMA-11 PET/CT derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1862–72.
Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, et al. Ga68-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019;33(10):766–75.
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with (Lu177) Lu-PSMA-617 A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113–22.
Ahmadzadehfar H, Matern R, Baum RP, Seifert R, Kessel K, Bögemann M, et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving (Lu177) Lu-PSMA-617:a WARMTH multicentre study. Eur J Nucl Med Mol Imaging. 2021;48:4067–76.
Peter MacCallum Cancer Centre A. Lu177-PSMA-617 therapy and olaparib in patients with metastatic castration resistant prostate cancer. 2020. https://ClinicalTrials.gov/show/NCT03874884
Acknowledgements
None.
Funding
We have made use of the medical equipment provided by Suleyman Demirel University, Faculty of Medicine, Department of Nuclear Medicine, Department of Medical Oncology. We have received no funding from any source.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Erdogan, M., Sengul, S.S., Cetin, B. et al. The role of Ga68 PSMA PET/CT imaging in Lu177 PSMA treatment planning in metastatic castration-resistant prostate cancer. Ann Nucl Med 36, 562–569 (2022). https://doi.org/10.1007/s12149-022-01739-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-022-01739-3